Exelixis Inc Paid-in-Kind Interest
Exelixis Inc (EXEL) reported Paid-in-Kind Interest of $0 for the 12-month period ending 2018-12-28, per its 10-K filed 2019-02-22.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2019-02-22
- Exelixis Inc paid-in-kind interest for the quarter ending 2018-12-28 was $0.00.
- Exelixis Inc paid-in-kind interest for the quarter ending 2018-09-28 was $0.00.
- Exelixis Inc paid-in-kind interest for the quarter ending 2018-06-29 was $0.00.
- Exelixis Inc paid-in-kind interest for the quarter ending 2018-03-30 was $0.00, a 100.00% decline year-over-year.
- Exelixis Inc paid-in-kind interest for fiscal 2018 was $0.00.
- Exelixis Inc paid-in-kind interest for fiscal 2017 was -$11.82M, a 247.66% decline from fiscal 2016.
- Exelixis Inc paid-in-kind interest for fiscal 2016 was $8.01M.
- Exelixis Inc paid-in-kind interest for fiscal 2016 was $8.01M, a 109.80% increase from fiscal 2016.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|
| 2018-12-28 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $0.00 derived: sum of 2 quarters · filed 2019-02-22 | $0.00 derived: sum of 3 quarters · filed 2019-02-22 | $0.00 10-K · filed 2019-02-22 |
| 2018-09-28 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $0.00 derived: sum of 2 quarters · filed 2018-11-01 | $0.00 10-Q · filed 2018-11-01 | $0.00 derived: sum of 4 quarters · filed 2019-02-22 |
| 2018-06-29 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $0.00 10-Q · filed 2018-08-01 | $0.00 derived: sum of 3 quarters · filed 2019-02-22 | $0.00 derived: sum of 4 quarters · filed 2019-02-22 |
| 2018-03-30 | $0.00 10-Q · filed 2018-05-02 | $0.00 derived: sum of 2 quarters · filed 2019-02-22 | $0.00 derived: sum of 3 quarters · filed 2019-02-22 | |
| 2017-12-29 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $0.00 derived: sum of 2 quarters · filed 2019-02-22 | -$11.82M 10-K · filed 2019-02-22 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | -$11.82M 10-Q · filed 2017-11-01 | ||
| 2017-09-29 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$13.89M derived: sum of 2 quarters · filed 2018-11-01 | -$11.82M 10-Q · filed 2018-11-01 | -$9.76M derived: sum of 4 quarters · filed 2018-11-01 |
| 2017-06-30 | -$13.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | -$11.82M 10-Q · filed 2017-08-02 | -$9.76M derived: sum of 3 quarters · filed 2018-05-02 | -$7.72M derived: sum of 4 quarters · filed 2018-05-02 |
| 2017-03-31 | $2.07M 10-Q · filed 2017-05-01 | $4.14M derived: sum of 2 quarters · filed 2018-05-02 | $6.17M derived: sum of 3 quarters · filed 2018-05-02 | $8.14M derived: sum of 4 quarters · filed 2018-05-02 |
| 2016-12-31 | $2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $4.10M derived: sum of 2 quarters · filed 2017-11-01 | $6.07M derived: sum of 3 quarters · filed 2017-11-01 | $8.01M 10-K · filed 2017-02-27 |
| 2016-12-30 | $8.01M 10-K · filed 2019-02-22 | |||
| 2016-09-30 | $2.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $4.00M derived: sum of 2 quarters · filed 2017-11-01 | $5.94M 10-Q · filed 2017-11-01 | $7.87M derived: sum of 4 quarters · filed 2017-11-01 |
| 2016-06-30 | $1.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $3.91M 10-Q · filed 2017-08-02 | $5.83M derived: sum of 3 quarters · filed 2017-08-02 | $7.72M derived: sum of 4 quarters · filed 2017-08-02 |
| 2016-03-31 | $1.94M 10-Q · filed 2017-05-01 | $3.86M derived: sum of 2 quarters · filed 2017-05-01 | $5.75M derived: sum of 3 quarters · filed 2017-05-01 | $5.75M derived: sum of 4 quarters · filed 2017-05-01 |
| 2016-01-01 | $3.82M 10-K · filed 2018-02-26 | |||
| 2015-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $3.82M derived: sum of 2 quarters · filed 2017-02-27 | $3.82M derived: sum of 3 quarters · filed 2017-02-27 | $3.82M 10-K · filed 2017-02-27 |
| 2015-09-30 | $1.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $1.89M derived: sum of 2 quarters · filed 2016-11-03 | $1.89M 10-Q · filed 2016-11-03 | $1.89M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $0.00 10-Q · filed 2016-08-03 | $0.00 derived: sum of 3 quarters · filed 2017-02-27 | |
| 2015-03-31 | $0.00 10-Q · filed 2016-05-04 | $0.00 derived: sum of 2 quarters · filed 2017-02-27 | ||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $0.00 10-K · filed 2017-02-27 | ||
| 2014-09-30 | $0.00 10-Q · filed 2015-11-10 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |